$0.93

0.02 (2.11%)

General Information

Viralytics Limited
VLA
http://www.viralytics.com
Biotechnology
225
237

Current Price Data+

Current Price $0.930
Open $0.940
High $0.940
Low $0.930
Last Close $0.950
Volume 9354
Price Movement $0.02 ( 2.11% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Stock Price

Current Broker Consensus Recommendation

Buy
27 May 2016
1

Company Overview

Business Description

Viralytics Ltd (VLA) is an Australian biotechnology company focusing on developing oncolytic virotherapy for the treatment of a range of cancers. VLA's principal asset is the intellectual property relating to CAVATAK, an Oncolytic Virus Technology, and is in current product development and pipeline. VLA holds granted patents in all major markets including the USA and Europe.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2017 F 0.0 13.3 0.0% 7.1 0.0 0.0% 0.0%
2016 F 0.0 -3.9 0.0% 0.0 0.0 0.0% 0.0%
2015 A -4.3 -2.3 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2015 A 2016 F 2017 F 2015 A 2016 F 2017 F 2015 A 2016 F 2017 F
CSL (CSL) $52,947M 0.3109 0.0617 0.2226 30.9034 29.1064 23.8064 1.40% 1.47% 2.08%
Mesoblast (MSB) $725M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $427M 1.8016 0.1736 0.0347 17.6043 15.0000 14.4968 3.83% 4.67% 4.83%
Sirtex Medical (SRX) $1,794M 0.6876 0.4570 0.4486 44.9498 30.8518 21.2970 0.64% 0.95% 1.37%
Viralytics (VLA) $225M 0.0000 0.0000 0.0000 0.0000 0.0000 7.1375 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 7.03 0.00
Market 1.15 15.90 1.18 0.71
Sector 0.49 18.50 3.31 0.71

Directors

Name Position Start Date
Dr Malcolm McColl Chief Executive Officer, Managing Director 8 Sep 2014
Mr Paul Hopper Non-Executive Chairman 4 Sep 2008
Mr Peter R Turvey Non-Executive Director 8 Sep 2014
Dr Leonard Post Non-Executive Director 21 Nov 2011

Management

Name Position
Robert Vickery Chief Financial Officer
Darren Shafren Chief Scientific Officer
Sarah Prince Company Secretary

Substantial Shareholders

Holding Name
22,931,933 (12.46%) BVF Partners LP
16,420,361 (8.92%) Cormorant Global Healthcare Master Fund, LP
11,288,998 (6.14%) Abingworth LLP
10,671,786 (5.80%) Sabby Healthcare Volatility Master Fund Limited

Calendar of Events

Date Event
21 February 2017 Report (Interim)
24 August 2016 Report (Prelim)
24 August 2016 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.